依达拉奉联合低分子肝素钙治疗进展性脑梗死疗效分析

Analysis of edaravone combined with low-molecular-weight heparin in the treatment of progressive cerebral infarction

目的观察依达拉奉联合低分子肝素钙治疗进展性脑梗死的疗效。方法选择进展性脑梗死住院患者60例,治疗组30例应用依达拉奉联合低分子肝素钙,对照组30例给予低分子肝素钙,2组其他治疗相同。结果治疗组总有效率明显优于对照组(P<0.01),治疗组治疗后超敏C反应蛋白(hs-CRP)明显下降。结论低分子肝素钙联合依达拉奉治疗进展性脑梗死安全有效,值得临床推广。

Objective To discuss the clinical effect of edaravone combined with low-molecular-weight heparin in the treatment of progressive cerebral infarction. Methods Sixty cases of progressive cerebral infarction patients were randomly divided into treatment group and control group. Control group used low-molecular-weight heparin, treatment group used edaravone additionally. Results General effective rate of the treatment group was 93.3%, the control group was 70% （P〈0.01）. There was an apparent different in high-sensitivity C-reactive protein （hs-CRP） between the treatment group and the control group （P d0.01）. Couclusion Combination of edaravone with low-molecular-weight heparin is effective and safe in the treatment of progressive cerebral infarction,and worthy to be popularized.